Jaguar Animal Health, Inc., an animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals, foals, and high value horses. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of chemotherapy-induced diarrhea and acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend for feline herpes and NP-500 for Type II diabetes and metabolic syndrome. The company was founded in 2013 and is headquartered in San Francisco, California.
Trade Type
| ReliabilityScore™
| Entry Date
| Entry Price
| Sell Date
| Sell Price
| Net Gain
| Hold Time
|